Eli Lilly (LLY) debt: $40.9B
Eli Lilly had $40.9B of long-term debt on Dec 31, 2025, including the part due within a year, up 38.7% from $29.5B a year earlier.
From Eli Lilly's filings with the SEC · Read the filing · LLY stock page
Eli Lilly debt by year
#37 of 2,129 US companies by debt · See the full ranking
| Year ended | Debt | Change |
|---|---|---|
| Dec 31, 2025 | $40.9B | +39% |
| Dec 31, 2024 | $29.5B | +54% |
| Dec 31, 2023 | $19.1B | +29% |
| Dec 31, 2022 | $14.8B | -12% |
| Dec 31, 2021 | $16.7B | – |
Debt of similar companies
Companies in the same industry as Eli Lilly, by SEC industry code, with the closest debt. Each name opens the same page for that company.
| Company | Debt, latest year | Year ended |
|---|---|---|
| Pfizer | $64.6B | Dec 31, 2025 |
| AbbVie | $64.5B | Dec 31, 2025 |
| Merck | $49B | Dec 31, 2025 |
| Bristol Myers Squibb | $44.8B | Dec 31, 2025 |
| Johnson & Johnson | $41.4B | Dec 28, 2025 |
| Eli Lilly | $40.9B | Dec 31, 2025 |
| Bausch Health Companies | $20.8B | Dec 31, 2025 |
Questions and answers
What is Eli Lilly's debt?
Eli Lilly had $40.9B of long-term debt on Dec 31, 2025, including the part due within a year, up 38.7% from $29.5B a year earlier.
Numbers as reported in Eli Lilly's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology